Pulse Biosciences
3957 Point Eden Way
Hayward
CA
94545
United States
Tel: 833-257-3393
Website: https://www.pulsebiosciences.com/
About Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company pursuing commercial introduction of our proprietary CellFX® System initially to the dermatology market. The CellFX System is powered by Nano-Pulse Stimulation™ (NPS™) technology, which delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular skin tissue. The unique cell-specific effects have the potential to significantly benefit patients across multiple medical applications. Designed as a multi-application platform, the initial commercial use of the CellFX System (upon regulatory approval) is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes.
Stock Symbol: PLSE
97 articles with Pulse Biosciences
-
Pulse Biosciences Schedules Third Quarter 2020 Financial Results Conference Call for November 9, 2020
10/28/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter 2020 after market close on Monday, November 9, 2020. Company management will host a corresponding conference call beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing
-
Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting
10/7/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinical results from studies spanning the Company’s dermatologic application portfolio will be presented at the American Society for Dermatologic Surgery (ASDS) virtual annual meeting on October 9-11, 2020.
-
Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study
10/1/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX® System. The data generated from
-
Pulse Biosciences Announces Receipt of MDSAP Certification
9/29/2020
Achieving ISO-13485:2016 MDSAP Certification Affirms the Company’s Quality Management Systems Meet FDA, Health Canada and CE Mark Requirements HAYWARD, Calif.--( BUSINESS WIRE )-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the receipt of Medical Device Single Audit Program certification. The Medical Device Single Audit Program (MDSAP) allows
-
Pulse Biosciences Grants Equity Incentive Awards To New Employees - Sep 15, 2020
9/15/2020
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 77,250 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 15, 2020.
-
Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference
9/1/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to virtually participate in the upcoming H.C. Wainwright Global Investment Conference.
-
Pulse Biosciences Reports Second Quarter 2020 Financial Results
8/10/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter ended June 30, 2020.
-
Pulse Biosciences, Inc. Appoints Richard van den Broek to Board of Directors
8/6/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS™) technology, announced today the appointment of Richard van den Broek to its board of directors
-
Pulse Biosciences Schedules Second Quarter 2020 Financial Results Conference Call for August 10, 2020
7/27/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, announced today it will report financial results for the second quarter 2020 after market close on Monday, August 10, 2020.
-
Nano-Pulse Stimulation™ Technology Produces Favorable Results in Several Clinical Studies Presented at the 2020 Laser Medicine and Surgery Virtual Annual Conference
7/1/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, today announced that three clinical studies demonstrating positive results across its dermatologic portfolio are available via webcast at the virtual annual conference of the American Society for Laser Medicine and Surgery (ASLMS).
-
Pulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering
6/17/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, announced today the closing of its oversubscribed rights offering and the final results thereof.
-
Pulse Biosciences, Inc. Announces Further Details of Oversubscribed Rights Offering
6/10/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, announced today further details of its rights offering, which expired on June 8, 2020. Based on a preliminary tabulation by Broadridge Corporate Issuer Solutions, Inc. (the “Subscription Agent”), as of the Expiration Date, the Company received basic subscriptions and over-subscriptions for 7,962,587 u
-
Pulse Biosciences, Inc. Announces Preliminary Results for Its Oversubscribed Rights Offering
6/8/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced preliminary results of its rights offering, which expired at 5:00 p.m. Eastern Time on June 8, 2020 (the “Expiration Date”).
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
5/14/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has commenced its previously-announced rights offering of up to 4,279,600 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below) with an aggregate offering value of up to $30,000,000
-
Pulse Biosciences Reports First Quarter 2020 Financial Results
5/11/2020
Pulse Biosciences, Inc., a novel bioelectric medicine company, announced financial results for the first quarter ended March 31, 2020.
-
Pulse Biosciences, Inc. Announces Updated Structure, Dates and Pricing Terms for Rights Offering
5/1/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has updated the structure, key dates and pricing terms for its previously-announced rights offering.
-
Pulse Biosciences Schedules First Quarter 2020 Financial Results Conference Call for May 11, 2020
4/29/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020.
-
Pulse Biosciences Files Registration Statement for Rights Offering
4/6/2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”, or “Pulse Biosciences”) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - March 17, 2020
3/17/2020
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 102,500 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on March 16, 2020.